DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CETROTIDE

« Back to Dashboard

All Clinical Trials for Cetrotide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00298025	A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation	Completed	EMD Serono	Phase 4	2003-09-01	To demonstrate the comparative safety and efficacy of Cetrotide® 3 milligram (mg) and Antagon™ in the inhibition of a premature luteinizing hormone (LH) surge in women undergoing ovarian stimulation with recombinant human follicle stimulating hormone/human menopausal gonadotropin (r-hFSH/hMG) prior to assisted reproductive technology (ART) and utilizing oral contraceptives pill (OCP) for cycle programming.
NCT00439829	Synchronization of Follicle Wave Emergence and Ovarian Stimulation	Completed	Royal University Hospital Foundation	Phase 4	2007-02-01	The objective of the study is to elucidate the effect of synchronizing initiation of ovarian stimulation treatment with follicular wave emergence in poor responder patients undergoing IVF/ICSI and ET. We hypothesize that initiating treatment on day 1 versus day 4 of the cycle will increase the number of follicles recruited and oocytes retrieved.
NCT00439829	Synchronization of Follicle Wave Emergence and Ovarian Stimulation	Completed	University of Saskatchewan	Phase 4	2007-02-01	The objective of the study is to elucidate the effect of synchronizing initiation of ovarian stimulation treatment with follicular wave emergence in poor responder patients undergoing IVF/ICSI and ET. We hypothesize that initiating treatment on day 1 versus day 4 of the cycle will increase the number of follicles recruited and oocytes retrieved.
NCT00460642	GnRH Antagonist to Prepare Recipients for Embryo Transfer	Completed	Institute for Human Reproduction (IHR)	N/A	2007-01-01	26% of all ART cycles performed in the USA in 2003 (CDC data) are frozen embryo transfers (FET) and transfer of embryos resulting from egg donation (ED) to recipients. The typical protocol used to prepare a recipient for ET involves GnRH agonist (Lupron, Tap Pharmaceuticals) to down regulate the patient. A GnRH antagonist, such as Cetrotide (EMD Serono), is comparable to GnRH agonist and FDA approved to prevent spontaneous ovulation with ART treatment, and its usage decreases significantly the number of injections that the patient receives with treatment. The working hypothesis for this study is that the GnRH antagonist (Cetrotide) can be used instead of an agonist to achieve effective down regulation in FET and ED cycles. Presumably, patients will prefer Cetrotide over Lupron because of the markedly fewer injections required.

Clinical Trial Conditions for Cetrotide

Condition Name

Condition Name for Cetrotide
Intervention	Trials
INFERTILITY	19
Subfertility	5
Invitro Fertilization	3
In Vitro Fertilization	2

Condition MeSH

Condition MeSH for Cetrotide
Intervention	Trials
Infertility	28
Polycystic Ovary Syndrome	3
Syndrome	3
Ovarian Hyperstimulation Syndrome	3

Clinical Trial Locations for Cetrotide

Trials by Country

Trials by Country for Cetrotide
Location	Trials
Egypt	14
United States	5
Spain	3
India	3
Iran, Islamic Republic of	2

Trials by US State

Trials by US State for Cetrotide
Location	Trials
Texas	1
Colorado	1
Virginia	1
Maryland	1
Illinois	1

Clinical Trial Progress for Cetrotide

Clinical Trial Phase

Clinical Trial Phase for Cetrotide
Clinical Trial Phase	Trials
Phase 4	14
Phase 3	10
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for Cetrotide
Clinical Trial Phase	Trials
Completed	22
Recruiting	14
Not yet recruiting	6

Clinical Trial Sponsors for Cetrotide

Sponsor Name

Sponsor Name for Cetrotide
Sponsor	Trials
Cairo University	11
Merck KGaA	4
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	2

Sponsor Type

Sponsor Type for Cetrotide
Sponsor	Trials
Other	48
Industry	8
NIH	2